Kennedy M P, Jimenez C A, Bruzzi J F, Mhatre A D, Lei X, Giles F J, Fanning T, Morice R C, Eapen G A
Department of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Thorax. 2008 Apr;63(4):360-5. doi: 10.1136/thx.2007.084079. Epub 2007 Oct 26.
The diagnostic accuracy of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for the diagnosis of lymphoma in patients with mediastinal lymphadenopathy is not well defined.
A retrospective review was performed of all patients with mediastinal lymphadenopathy referred for EBUS-TBNA between August 2005 and December 2006 in whom lymphoma was suspected based on prior history or clinical presentation. Mediastinal biopsy specimens were taken using a linear array ultrasonic bronchoscope (Olympus XBF-UC 160F) and a 22-gauge cytology needle (NA-202C Olympus) with on-site cytopathological support. The EBUS-TBNA result was compared with a reference standard of pathological tissue diagnosis or a composite of > or =6 months of clinical follow-up with radiographic imaging.
Of 236 patients who underwent EBUS-TBNA, 25 were eligible for inclusion. Indications for EBUS-TBNA were suspected mediastinal recurrence of lymphoma (n = 13) and mediastinal lymphadenopathy of unknown cause (n = 12). Adequate lymph node sampling was accomplished in 24/25 patients (96%); there were no complications. EBUS-TBNA identified lymphoma in 10 patients and benign disease in 14 patients. There was one false negative EBUS-TBNA for lymphoma (lymphoma prevalence 11/25 (44%)). Follow-up over a median of 10.5 months (range 1-19) confirmed stable or regressive lymphadenopathy in all 14 patients without a lymphoma diagnosis, consistent with a benign diagnosis. Overall, EBUS-TBNA had a sensitivity of 90.9%, specificity of 100%, positive predictive value of 100% and negative predictive value of 92.9% for the diagnosis of lymphoma.
EBUS-TBNA is an accurate, safe and useful tool in the investigation of suspected lymphoma with isolated mediastinal adenopathy, and may diminish the need for more invasive procedures such as mediastinoscopy.
对于纵隔淋巴结肿大患者,支气管内超声引导下经支气管针吸活检术(EBUS-TBNA)诊断淋巴瘤的准确性尚不明确。
对2005年8月至2006年12月期间因纵隔淋巴结肿大而接受EBUS-TBNA检查、且根据既往病史或临床表现怀疑患有淋巴瘤的所有患者进行回顾性研究。使用线性阵列超声支气管镜(奥林巴斯XBF-UC 160F)和22号细胞学针(奥林巴斯NA-202C)在现场细胞病理学支持下获取纵隔活检标本。将EBUS-TBNA结果与病理组织诊断的参考标准或≥6个月的临床随访及影像学检查结果进行比较。
在236例行EBUS-TBNA检查的患者中,25例符合纳入标准。EBUS-TBNA的适应证为疑似淋巴瘤纵隔复发(n = 13)和病因不明的纵隔淋巴结肿大(n = 12)。24/25例患者(96%)实现了充分的淋巴结采样;无并发症发生。EBUS-TBNA确诊10例淋巴瘤患者,14例为良性疾病。EBUS-TBNA对淋巴瘤的诊断有1例假阴性(淋巴瘤患病率11/25(44%))。中位随访10.5个月(范围1 - 19个月)证实,所有14例未诊断为淋巴瘤的患者淋巴结肿大稳定或缩小,符合良性诊断。总体而言,EBUS-TBNA诊断淋巴瘤的敏感性为90.9%,特异性为100%,阳性预测值为100%,阴性预测值为92.9%。
EBUS-TBNA是调查孤立性纵隔淋巴结肿大疑似淋巴瘤的一种准确、安全且有用的工具,可能会减少对诸如纵隔镜检查等侵入性更强的检查的需求。